Macquarie Group LTD Gritstone Bio, Inc. Transaction History
Macquarie Group LTD
- $85.1 Billion
- Q2 2024
A detailed history of Macquarie Group LTD transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 4,562 shares of GRTS stock, worth $2,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,562Holding current value
$2,782% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GRTS
# of Institutions
83Shares Held
37.5MCall Options Held
1.46MPut Options Held
168K-
Redmile Group, LLC San Francisco, CA5.11MShares$3.12 Million0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.64MShares$2.83 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.45MShares$2.72 Million0.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA3.56MShares$2.17 Million4.9% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL3.46MShares$2.11 Million0.01% of portfolio
About Gritstone bio, Inc.
- Ticker GRTS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,006,896
- Market Cap $44.5M
- Description
- Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...